The rest of this page explains how that axis works, what adults can reasonably expect, which side effects turn up most often, why these substances sit on anti-doping lists, and which blood markers are worth putting in front of a clinician before anything in this category is considered.
A peptide is a short chain of amino acids, shorter than a protein, that acts as a signal rather than as building material. Your body makes thousands of them. Insulin is a peptide. So is the hypothalamic messenger that tells the pituitary gland when to release growth hormone. That is the entire commercial logic of this category, because a molecule that imitates a natural signal can, in principle, turn a biological dial that diet and training move only slowly.
Almost none of the peptides marketed for muscle act on muscle tissue directly. Most work upstream, prompting the pituitary to release more growth hormone in its own pulsing rhythm, or imitating the downstream messenger that growth hormone sends out to tissues. A second group is marketed for tendon, ligament or cartilage repair rather than size, on the argument that faster recovery allows more frequent hard training.
What is sold and what has actually been tested in people are two different lists. A review of peptide therapies used for musculoskeletal injury and athletic performance reports that many compounds circulating in this space are unapproved for the uses they are advertised for, and that human safety data is thin for several of them 1.
One clarification before going further. Collagen peptides and protein powders are food. They are nutritional protein, not signalling therapy, and they belong in a different conversation from anything injected or prescribed.
Nearly all of them target one chain of command, the growth hormone to IGF-1 axis. The hypothalamus releases a signal, the pituitary answers with bursts of growth hormone (most of them at night and after hard exercise), and the liver and other tissues respond by producing insulin-like growth factor 1. Growth hormone itself has a short life in the blood and comes in pulses. IGF-1 circulates more steadily, bound to carrier proteins, which is why it is the marker clinicians usually look at when they want a picture of the axis.
The two halves of the axis do different jobs. Growth hormone pushes fat tissue to release fatty acids, influences how the body handles sodium and water, and blunts the action of insulin. IGF-1 is the growth signal proper. It acts on muscle fibres and on the satellite cells that repair and add to them, which is why this axis is so often described in the language of muscle building.
That chain is also why growth hormone and IGF-1 appear together on anti-doping lists, alongside insulin and erythropoietin, as substances misused in sport for their anabolic and recovery effects 2. Understanding the axis matters here for a practical reason. A product that raises growth hormone does not deliver a clean anabolic signal on its own. It raises everything else growth hormone does at the same time, including the effects on fluid and on blood sugar.
In adults who do not have a diagnosed deficiency, the honest answer is that the scale moves more than the lifts do. Research suggests that growth hormone in older adults shifts body composition, raising lean mass and lowering fat mass, without reliably improving strength, physical function or quality of life 3. That gap between a body composition number and a performance number is the single most important thing to understand before considering anything in this category.
The situation is genuinely different in people with a diagnosed growth hormone deficiency, where a specialist is correcting a measured shortfall rather than pushing a normal system higher, and where the risk and benefit calculation is assessed individually 3. That is a clinical diagnosis made from a full endocrine workup, not something read off a single blood value or inferred from feeling tired and training poorly.
It is also worth being precise about what the sales pitch borrows from. Much of the enthusiasm for this category comes from laboratory and animal work, where a growth signal applied to tissue does what a growth signal does. That does not carry over to a prediction about muscle in a healthy adult who trains three times a week.
Because lean mass, as a scan or a bioimpedance device reports it, is everything in the body that is not fat and not bone, and that includes water. Growth hormone changes how the body handles sodium and fluid, and fluid retention is one of the most consistently reported effects of growth hormone use in adults 4. Extra total body water lands in the lean mass column of a report, which can look like several pounds of new muscle in a few weeks, a speed real muscle tissue cannot match.
There is a second reason. Not all protein in muscle is contractile. Connective tissue inside and around muscle is protein too, and an increase in tissue protein synthesis does not automatically translate into more force-producing fibres. The measurable outcome that matters to a person is what they can lift, how fast they walk, how easily they get off the floor, and reviews of growth hormone and IGF-1 use in sport report limited evidence that these substances improve athletic performance in the way users expect 2.
Practically, this means body composition scans are a poor way to judge this category. If someone is considering it, the honest tracking tools are strength logs, walking speed, grip strength and how recovery actually feels, measured over months rather than weeks. Numbers that rise within days are usually telling you about water.
Fluid retention, joint pain and effects on blood sugar lead the list. A systematic review of growth hormone use in older patients with other medical conditions reports swelling, joint pain, carpal tunnel type symptoms and impaired glucose handling among the adverse effects observed 4. Those are not exotic outcomes. They are the predictable extensions of what the hormone does to fluid balance and to insulin sensitivity.
The glucose effect deserves its own line. Growth hormone opposes insulin, so a rise in fasting glucose or a drift upward in HbA1c is a recognised concern with use in adults 3. For someone who already sits at the upper end of the standard range for either marker, that is a meaningful consideration and exactly the kind of thing a prescriber weighs before anything else is discussed.
There is also the question of long-term exposure to a growth signal. None of this makes a lab value a verdict about a person. It makes the point that this axis is not a free lever.
If swelling, persistent joint pain, numbness or tingling in the hands, unusual thirst or rapid unexplained weight change appear while using anything in this category, that is worth discussing with a clinician promptly rather than waiting for a scheduled retest.
Because anti-doping bodies classify growth hormone and IGF-1 as performance-enhancing agents, and they sit alongside insulin and erythropoietin in the sports endocrinology literature on doping 2. For any athlete subject to testing, from international competition down to many amateur federations and collegiate programmes, use carries the risk of sanction regardless of how a product was obtained or what the label on the vial said.
If you compete under any testing authority, the only reliable move is to check the current prohibited list published by that authority and to clear anything, including supplements, with your team physician before use.
It means no regulator has reviewed that product, for that purpose, at that level of exposure, and concluded that the benefits outweigh the risks. Approval is specific to an indication. A molecule can be approved for a narrow clinical condition and still be unapproved, and essentially untested, for muscle gain in healthy adults. A review of peptide therapies used for musculoskeletal injury and athletic performance describes exactly this split between approved uses and the much wider unapproved marketplace 1.
A great deal of what circulates online sits outside the medical system entirely, sold with 'laboratory use only' or 'not for human consumption' labelling. That wording is not a technicality. It signals a product made without the manufacturing controls that apply to medicines, and sold without anyone taking responsibility for what happens to a person who injects it.
The same caution applies to the injury-repair corner of this category. A review of injectable therapeutic peptides in regenerative medicine and sports settings describes the human data as limited and the regulatory position as unsettled 5. Early interest in a mechanism is not the same as a demonstrated benefit in people, and this page will not pretend otherwise.
Whatever your conclusion about a given product, the decision to start, stop or change any prescription therapy belongs to a licensed provider who has evaluated you.
Enough that two vials with identical labels can contain different things. Products made outside pharmaceutical manufacturing standards vary in purity, in actual content versus label content, and in contamination, and safety concerns around unapproved peptide products in sport and musculoskeletal medicine are documented in the review literature on this category 1.
That variability creates a problem that no amount of careful self-management solves. If you do not know what is in the vial, you cannot interpret what happens next. A side effect might come from the molecule, from a contaminant, from a solvent or from something that is not on the label at all. A good outcome is equally uninterpretable. This is the practical reason to work inside a clinical relationship rather than self-sourcing, not a moral one.
What a licensed provider adds is accountability and a record. Someone takes a history, looks at your baseline labs, documents what was used and why, decides whether a given option is appropriate for you at all, and is responsible for following up on what changes. Compounded preparations in particular are dispensed under a prescriber's judgement, and that judgement is the control that an anonymous online purchase does not have.
This page does not discuss where to obtain anything, and it gives no doses, schedules or administration steps for any peptide or prescription therapy. Those belong to a prescriber, in a consultation, after an evaluation.
Weakest where the marketing is loudest. The table below grades the common claims by what human data actually supports, which is the distinction most product pages blur.
| Common claim | What human evidence supports | Practical read |
|---|---|---|
| Adds muscle fast | Growth hormone in adults is associated with higher lean mass and lower fat mass, with fluid retention contributing to the lean figure 3 4 | A scan number moving is not the same as muscle you can use |
| Makes you stronger and faster | Reviews of growth hormone and IGF-1 in sport report limited evidence of improved performance 2 | Strength tracking, not body composition, is the honest test |
| Speeds tendon and joint repair | Human data for injectable peptides in this role is limited and preliminary 5 1 | Treat as unsettled, not established |
| Holds off age-related muscle loss | Research suggests growth hormone in older adults changes body composition without reliable functional gain 3 | Resistance exercise has the stronger human record 6 |
| Safe because it is natural to the body | Swelling, joint pain and impaired glucose handling are reported with growth hormone use in older adults 4 | Side effects are predictable, not rare surprises |
Two rules make this easier to read on any product page you come across. Laboratory and animal findings say nothing reliable about what happens in a trained adult. And a claim about body composition is not a claim about function, however it is phrased.
Mechanical load, adequate protein, enough total energy, sleep and time. That list is unglamorous and it is still the part with the strongest human track record. Resistance exercise is described as the central approach to building and preserving muscle in the literature on age-related muscle loss 6, and a review of medications for sarcopenia describes exercise and nutrition as the foundation while pharmacological agents remain investigational 7.
In practice that means progressive resistance training, where load, reps or quality rise over months, covering the major movement patterns a few times a week. It means protein spread across the day rather than stacked into one meal, from whole foods where possible. It means not running a large energy deficit while expecting new tissue, because muscle is expensive to build. It means sleeping enough that the overnight growth hormone pulse and the recovery that goes with it actually happen.
These factors also set the ceiling on anything else. No signalling molecule creates muscle from a stimulus that was never applied or protein that was never eaten. Someone whose training is inconsistent and whose protein intake is low has a far larger lever available than anything discussed on the rest of this page, and it costs nothing and carries no side effect profile.
Age-related loss of muscle mass and strength, called sarcopenia, is a real clinical concern, and it is the setting where this whole category is most often marketed. The mechanisms involve changes in nerve supply to muscle, hormonal shifts, inflammation, reduced activity and lower protein intake, and resistance exercise is the intervention with the most consistent support 6.
On the pharmacological side, a review of current and investigational medications for sarcopenia describes a field where options remain under study rather than established, with exercise and nutrition still the base of care 7. Growth hormone specifically has been examined in older adults, and research suggests it alters body composition without delivering reliable improvements in strength or function, while carrying side effects 3.
That matters because older adults are also the group most exposed to the downsides. Impaired glucose handling, swelling and joint pain are reported in older patients with coexisting conditions 4, and the person most attracted by an anti-ageing pitch is often the person with the most to lose from those effects. A clinician who knows your full history is the right person to weigh that balance, not a product page.
Three in particular, IGF-1, fasting glucose and HbA1c, plus a broad baseline panel so that any change has something to be compared against. IGF-1 reflects the axis these products act on. Glucose and HbA1c cover the metabolic effect that shows up most predictably, since growth hormone opposes insulin action in adults 3.
| Marker | What it reflects | Why it matters here |
|---|---|---|
| IGF-1 | The steadier downstream signal of the growth hormone axis | The marker a clinician uses to see where your axis sits before and after any change |
| Fasting glucose | Blood sugar in the fasted state | Picks up a drift in glucose handling early |
| HbA1c | Average blood sugar exposure over recent months | Shows a slower trend that a single fasting reading can miss |
A wider baseline is useful too, including markers of kidney and liver function, thyroid markers, a full lipid panel and body composition measured the same way each time. FitScript's membership covers 150+ biomarkers tested per year with interpretation by Atlas, FitScript's AI health advisor, which is one way to have that baseline in place before any conversation about therapy rather than after it.
None of these numbers decides anything on its own. They give a prescriber a starting point and give you a way to notice change.
With a standard blood draw, usually fasted so that glucose is interpretable. Growth hormone itself is released in pulses and clears quickly, so a single random growth hormone level says very little, which is why IGF-1 is the more practical marker of where the axis sits. Reference ranges for IGF-1 are age and sex specific and vary between laboratories, so a result should always be read against the range printed on your own report.
The useful way to read any of these values is in three steps. First, the observation, which is simply where the number sits relative to the laboratory's range and to your own previous results. Second, what it may reflect, which can include age, nutrition, sleep, liver function, chronic illness, training load and, in a small number of people, a genuine endocrine problem. Third, the next step, which is a conversation with a clinician who can see the result alongside your history and symptoms.
What a result cannot do is diagnose you, confirm that a product is working, or predict how much muscle you will build. A suboptimal IGF-1 value in isolation is a prompt for a proper evaluation, not a reason to start anything. Equally, a result inside the standard range does not rule out a clinical problem if symptoms say otherwise. Retesting on a consistent schedule, under the same conditions, tells you far more than any single draw.
A licensed provider does, after an evaluation, and that holds for every prescription therapy and peptide without exception. The evaluation typically covers your medical history, current medications, symptoms, goals, baseline labs and the conditions that would make a given option unsuitable. The provider then decides whether anything is appropriate, including the common and entirely legitimate answer that nothing in this category fits your situation.
FitScript works with licensed providers across all 50 states; specific treatment availability can vary by state and is confirmed during your provider evaluation.
If you do have that conversation, a few questions make it more useful. What specifically is being addressed, and how will we know whether it worked. What human data support this use, and where are those data thin. Which side effects should prompt me to call. Which labs will be rechecked, and on what schedule. What happens if we stop. A provider who is comfortable saying 'the human data here is limited' is giving you better information than one who is not.
Two things no legitimate consultation includes are a recommendation to buy something yourself from an unregulated seller, and a promise about results. Outcomes vary between people, and anything in this category is clinician-gated and, in several corners, still experimental.
Before starting anything, and promptly if something changes. Worth raising at a scheduled visit are persistent fatigue, unexplained loss of muscle or strength, poor recovery from training that does not improve with better sleep and nutrition, or lab values outside the standard range on your report.
Worth raising promptly, rather than waiting, are swelling in the hands, feet or face, new or worsening joint pain, numbness or tingling in the hands, unusual thirst or urination, blurred vision, or rapid unexplained weight change, particularly while using anything that acts on this axis. These overlap directly with the fluid and glucose effects reported with growth hormone use in adults 4, and they are easier to deal with early. Never ignore an abnormal result, and never stop or change a prescribed therapy on your own.
This page is educational and not medical advice. Discuss your results and any decision about therapy with a clinician or licensed provider who knows your full history.
For related reading inside this topic, the overview of peptide therapy for men covers how a clinician-gated process works for male members, and the page on peptide and NAD+ care sets out how these categories are handled more broadly.
It depends entirely on the product and the country, and a lot of what is sold online sits outside the medical system with labelling such as 'laboratory use only'. Anything genuinely prescribable requires a licensed provider to evaluate you and decide whether it is appropriate. If you compete under any anti-doping authority, check that authority's current prohibited list before using anything at all.
No. Mechanical load, adequate protein, enough total calories and sleep are what build and preserve muscle, and nothing in this category creates tissue from a stimulus that was never applied. If training is inconsistent or protein intake is low, that is the larger lever and it carries no side effect profile. Any therapy sits on top of those basics, never instead of them.
IGF-1, fasting glucose and HbA1c are the core three, ideally alongside a broad baseline panel so later results have something to be compared against. IGF-1 reflects the axis these products act on, while glucose and HbA1c cover the metabolic effects worth watching. Have them drawn under consistent conditions so changes over time mean something.
No, a single value does not predict how much muscle you will build. IGF-1 reflects where your growth hormone axis is sitting and is influenced by age, sex, nutrition, sleep, liver function and illness. A result above or below your laboratory's range is a reason for a clinician to look at the wider picture, not a verdict on your training potential.
Effects on blood sugar are a recognised concern with anything acting on the growth hormone axis, which is why fasting glucose and HbA1c belong in the baseline and the follow-up. Unusual thirst, frequent urination or blurred vision are worth discussing with a clinician promptly. A provider decides what monitoring schedule fits your situation.
Age-related muscle loss is a real clinical concern, and it is also the pitch this category leans on hardest. Progressive resistance training and adequate protein have the strongest record, and older adults are also the group most exposed to side effects such as swelling, joint pain and changes in blood sugar. A clinician who knows your full history is the right person to weigh any option.
Because products made outside pharmaceutical manufacturing standards vary in purity and in what they actually contain, which makes both good and bad outcomes impossible to interpret. A provider takes a history, reviews your baseline labs, documents what is used and why, and follows up on what changes. That accountability is the part an anonymous purchase cannot provide.
That is set by your provider based on what is being monitored and why, rather than by a fixed rule. In general, retesting under the same conditions as your baseline, same fasting state and same laboratory where possible, makes trends far easier to read. Bring any new symptoms to the appointment, since they often change the testing plan.